Cardurion Pharmaceuticals Raises $260M in Series B Funding to Challenge Statin-Dominated Cardiovascular Market

1. Funding Amount: Cardurion Pharmaceuticals has raised $260 million in a Series B funding round.
2. Investors: The funding round was led by Ascenta Capital and included participation from Bain Capital, NEA, GV, Fidelity Management & Research Company, Millennium Management, Farallon Capital Management, Invus, Blue Owl Healthcare Opportunities, Delos Capital, and Digitalis Ventures.
3. Purpose: The funding aims to challenge the statin-dominated status quo in the cardiovascular market.
4. Previous Funding: Cardurion Pharmaceuticals received a $300 million investment from Bain Capital in 2021.
5. Company Focus: Cardurion Pharmaceuticals is a biotech company focused on cardiovascular health.